2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.09 Saini

PP01.09 Saini - Poster

Pdf Summary

The document discusses responses to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC), specifically focusing on patients with mutations in the STK11 gene (STK11MUT). Despite some patients with STK11 mutations responding to immunotherapies, the factors impacting their response remain unclear. The study analyzed clinicopathologic and genomic data from NSCLC patients treated with ICI, evaluating factors associated with response in STK11MUT patients. Results showed that a small subset of STK11MUT lung cancer patients responded well to immunotherapy, with PD-L1 expression and tumor mutational burden (TMB) being predictive of response. Additionally, patients without KRAS mutations or with non-frameshift mutations had improved progression-free and overall survival outcomes. The document concludes that PD-L1 expression, TMB, and specific mutation types are crucial factors influencing the efficacy of ICI in STK11MUT NSCLC patients. This analysis provides insights into optimizing treatment strategies for this molecular subgroup of NSCLC, offering valuable information for clinicians and researchers in the field.

Keywords

immune checkpoint inhibitors

non-small cell lung cancer

STK11 gene mutations

STK11MUT

immunotherapy response

PD-L1 expression

tumor mutational burden

KRAS mutations

progression-free survival

overall survival